Vistagen Therapeutics, INC 10-K annual reports

Vistagen Therapeutics reported mixed results for its fasedienol clinical trials, with two Phase 3 trials failing to meet primary endpoints, while also announcing a workforce reduction and continued focus on cash management.

Vistagen Therapeutics, a clinical-stage biopharmaceutical company, reported a significant increase in net losses and cash burn for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite positive clinical progress for its lead drug candidate, fasedienol, and other pipeline assets.

Vistagen Therapeutics reports its fiscal year 2024 results, highlighting progress in its clinical-stage neuroscience pipeline and strategic partnerships.